Mankind Pharma to acquire BSV’s women health portfolio in ₹797 crore deal

A Business Transfer Agreement (BTA) is a legal contract used to transfer a company’s business or specific division to another entity as a going concern.

The ₹797 crore deal covers BSV’s women health prescription portfolio, which will be transferred to Mankind Pharma as a going concern through a slump sale.

As a part of the agreement, 50% of the payment will be made at the time of closing, with the balance payable within 150 days.

“The completion of the above acquisition is subject to pre-conditions, closing actions and other terms & conditions as specified in the BTA,” the company said in an exchange filing.

Mankind Pharma share price

At close, the shares settled 0.62% lower at ₹2,464 per equity share on the National Stock Exchange (NSE). The announcement, however, was made after market hours.

Over the past five trading sessions, the company’s shares have jumped 2.20%, and further dropped 5.54% over the past month. On the contrary, the stock has gained 4.83% in the last six months and has declined 14.48% year-to-date.

Mankind Pharma's shares reached a 52-week high of ₹3,054.80 on December 23, 2024, and a 52-week low of ₹2,115.10 on March 18, 2025. As of October 10, the company’s market capitalisation stood at ₹1,01,703.69 crore.

About Mankind Pharma

Incorporated in 1991, Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

Mankind produces branded generic drugs sold throughout India, with a uniquely deep reach in rural and semi-urban markets.

In May 2023, Mankind Pharma's shares had a stellar debut on the bourses. The company's ₹4,326 crore IPO was one of the biggest by a domestic pharmaceutical player since Gland Pharma made its market debut with a ₹6,479.5 crore IPO in 2020, as per a PTI report.